IMTX Immatics
- 10.010
- +0.230+2.35%
Immatics News
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Immatics (NASDAQ:IMTX) Shareholders Are Still up 47% Over 1 Year Despite Pulling Back 7.9% in the Past Week
Immatics N.V. (NASDAQ:IMTX) shareholders have seen the share price descend 10% over the month. While that might be a setback, it doesn't negate the nice returns received over the last twelve months
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Express News | Immatics Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q4 Financial Results
Sector Update: Health Care Stocks Gain Pre-Bell Thursday
Health care stocks were gaining pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was up 0.7% recently. Immatics (IMTX) shares
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
Immatics N.V. Showcases Clinical Strides and Fiscal Health
Sector Update: Health Care
Health care stocks were gaining pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was up 0.6% recently. Immatics (IMTX) shares
Immatics Swings to 2023 Net Loss, Revenue Falls -- Shares Down Pre-Bell
Immatics (IMTX) reported a full-year 2023 net loss Thursday of 1.20 euros ($1.31) per diluted share, swinging from earnings of 0.55 euros a year earlier. Analysts polled by Capital IQ expected a loss
Express News | Immatics Q4 GAAP EPS €(1.20) Down From €0.55 YoY, Revenue From Collaboration Agreements €54.00M Down From €172.83M YoY; Cash And Cash Equivalents, And Other Financial Assets Of €425.9M (~$470.6M) Expected To Provide Cash Runway Into 2027
Press Release: Immatics Announces Full Year 2023 Financial Results and Corporate Update
Immatics Announces Full Year 2023 Financial Results and Corporate Update -- Interim clinical data update on ACTengine(R) IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirm
Immatics Announces Full Year 2023 Financial Results and Corporate Update
10 Health Care Stocks Whale Activity In Today's Session
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.
With 52% Institutional Ownership, Immatics N.V. (NASDAQ:IMTX) Is a Favorite Amongst the Big Guns
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Buy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnerships
Immatics N.V.'s (NASDAQ:IMTX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 7.3% Over the Past Week
Key Insights Institutions' substantial holdings in Immatics implies that they have significant influence over the company's share price The top 10 shareholders own 50% of the company Using data fr
Sector Update: Health Care Stocks Mixed Premarket Thursday
Health care stocks were mixed premarket Thursday as the iShares Biotechnology ETF (IBB) was 0.4% up and the Health Care Select Sector SPDR Fund (XLV) was down 0.8% recently. biote (BTMD) was slipping
Immatics Prices Upsized Stock Offering to Raise $175 Million
Immatics Is a Clinical-Stage Biopharmaceutical Company >IMTX
Immatics Is a Clinical-Stage Biopharmaceutical Company >IMTX
Analysis
Price Target
No Data
